塞来昔布
伊立替康
环氧合酶
医学
腹泻
药理学
拓扑异构酶
癌症
内科学
结直肠癌
化学
酶
生物化学
作者
Ovidiu C. Trifan,William F. Durham,Valerie S. Salazar,Jennifer Horton,Benjamin D. Levine,Ben S. Zweifel,Thomas W. Davis,Jaime L. Masferrer
出处
期刊:PubMed
日期:2002-10-15
卷期号:62 (20): 5778-84
被引量:63
摘要
Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated by late diarrhea. A number of studies have shown that cyclooxygenase (COX)-2 is overexpressed in many forms of human tumors, suggesting that COX-2 inhibition may be useful in the treatment of cancer. In this study, we used two mouse tumor models (HT-29 and colon-26 cells) to evaluate the effect of combining CPT-11 with celecoxib on tumor growth. We also assessed the involvement of COX-2 in the pathogenesis of CPT-11-induced late diarrhea using a rat model. Results indicate that celecoxib enhances the antitumor effect of CPT-11 and reduces the severity of late diarrhea in a dose-dependent manner. The extended benefits of combining celecoxib with CPT-11 may significantly improve the outcome of cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI